Underrepresentation of African-Americans in Alzheimer's Trials: A Call for Affirmative Action
Year: 2016
Type: article
Abstract: Personalized medicine aims to tailor diagnosis and treatment based on an individual's personal genetic make-up and other predictive biomarkers-rather than a one-size fits all approach.African-Americans comprise 13.2% of the U.S. population (U.S. Census Bureau, 2014) and minorities (consisting of all but non-Hispanic Caucasian), now 37% of the U.S. population, are projected to reach closer to 57% in 2060 (U.S. Census Bureau, 2012).Indeed in coming decades minority population, including African-Americans, may exceed the Caucasian population in the U.S.Dementia, especially Alzheimer's disease (AD), has emerged as one of the biggest threats to public health and personal wellbeing among older adults.Epidemiological studies, by nature of their community sampling, have been able to study risk for AD in racially representative populations.In such studies, older African-Americans have been reported as being more likely than older Caucasians to develop AD and other dementias (Gurland et al.,
Source: Frontiers in Aging Neuroscience
Authors: Jaewook Shin, P. Murali Doraiswamy
Institutions: Duke University, Duke Medical Center
Language: English
Topic: Ethics in Clinical Research
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W2412500390
